Baxter To Buy Prism, Getting Heart Drug | April 25, 2011 Issue - Vol. 89 Issue 17 | Chemical & Engineering News
Volume 89 Issue 17 | p. 21 | Concentrates
Issue Date: April 25, 2011

Baxter To Buy Prism, Getting Heart Drug

Department: Business
Keywords: hospital infusion

Baxter International has agreed to acquire Prism Pharmaceuticals, a privately held drug firm that recently received FDA approval for the antiarrhythmic agent Nexterone. Baxter will pay $170 million at closing and up to $168 million in sales-based milestones. Sold as a ready-to-use premixed intravenous bag, Nexterone requires no admixing, Baxter says, thus eliminating the risk of medication errors as a result of compounding. Prism had previously selected Baxter as its contract manufacturer.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment